eCite Digital Repository

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

Citation

Di Ciaccio, P and McCaughan, G and Trotman, J and Ho, PJ and Cheah, CY and Gangatharan, S and Wight, J and Ku, M and Quach, H and Gasiorowski, R and Polizzotto, MN and Prince, HM and Mulligan, S and Tam, CS and Gregory, G and Hapgood, G and Spencer, A and Dickinson, M and Latimer, M and Johnston, AM and Armytage, T and Lee, C and Cochrane, T and Berkhahn, L and Weinkove, R and Doocey, R and Harrison, SJ and Webber, N and Lee, H-P and Chapman, S and Campbell, BA and Gibbs, SDJ and Hamad, N, Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic, Internal Medicine Journal, 50, (6) pp. 667-679. ISSN 1444-0903 (2020) [Refereed Article]


Preview		PDF
Pending copyright assessment - Request a copy
659Kb		  

DOI: doi:10.1111/imj.14859

Abstract

The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources.

Item Details

Item Type:Refereed Article
Keywords:COVID-19, lymphoma, myeloma, chronic lymphocytic leukaemia
Research Division:Biomedical and Clinical Sciences
Research Group:Oncology and carcinogenesis
Research Field:Cancer cell biology
Objective Division:Health
Objective Group:Clinical health
Objective Field:Diagnosis of human diseases and conditions
UTAS Author:Johnston, AM (Dr Anna Johnston)
ID Code:150326
Year Published:2020
Web of Science® Times Cited:23
Deposited By:Medicine
Deposited On:2022-06-08
Last Modified:2022-06-20
Downloads:0

Repository Staff Only: item control page